For example, several European healthcare systems have expanded reimbursement for Wegovy in eligible obesity patients, supporting wider clinical adoption
Subscribe Now Demand from patients for obesity medication is unrelenting
You also have side effects
"It's a cynical money grab by Anthem, designed to take advantage of the commitment anesthesiologists make thousands of times each day to provide their patients with expert, complete and safe anesthesia care," the statement continued
For Evolocumab (Repatha), the common HCPCS code used is J3590 (Unclassified biologic) or sometimes J3490 (Unclassified drug), especially if a specific code isn't established, with billing often tied to the administration setting (like office-administered under Medicare Part B) or pharmacy benefit, requiring prior authorization and diagnosis codes like E78.01 (Familial Hypercholesterolemia) or ASCVD codes